随机试验比较SGLT2抑制和甲酸在2型糖尿病的交感流量
Karsten Heusser1, Jens Tank1, André Diedrich2,3
1Institute of Aerospace Medicine, German Aerospace Center, Cologne Germany.
Kidney international reports
|November 29, 2023
概括
在2型糖尿病患者中,使用empagliflozin抑制糖共运输体2 (SGLT2) 并没有显著改变肌肉交感神经活动 (MSNA). 然而,empagliflozin改变了体重减轻和MSNA之间的关系,这表明SGLT2特定的作用可能会减弱交感刺激.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 糖共传输体2 (SGLT2) 抑制剂可以改善心血管结果,可能通过减少交感神经系统活动.
- 了解SGLT2抑制对同情活动的特定影响对于辨别其心血管益处至关重要.
研究的目的:
- 为了调查SGLT2与empagliflozin (Empa) 抑制是否降低肌肉交感神经活动 (MSNA) 在2型糖尿病 (T2DM) 的患者.
- 为了比较empagliflozin与酸 (HCT) 对MSNA的影响,以区分SGLT2特异性的作用与对天然的反应.
主要方法:
- 一项随机,双盲,并行研究,涉及41名T2DM患者接受甲胺单疗.
- 参与者接受Empagliflozin (25 mg/d) 或Hydrochlorothiazide (25 mg/d) 的治疗,持续6周.
- 肌肉交感神经活动 (MSNA) 通过腹膜微神经图,以及血压和代谢生物标志物进行评估.
主要成果:
- 恩帕格利弗洛辛和甲都引起体积消耗和降低缩血压.
- 与甲相比,empagliflozin导致更大的体重减轻和改善血糖控制.
- 两种药物都没有显著改变MSNA,但empagliflozin转移了体重减轻和MSNA之间的负相关性,表明对交感激活的潜在减弱.
结论:
- 增加分泌和随后的体重减轻通常会促进交感激活.
- 用empagliflozin抑制SGLT2可能会减轻尽管有自然和体重减轻的同情刺激,这表明SGLT2特定的机制有助于心血管益处.
关键词:
在HCT中,HCT是HCT.调节心血管系统的调节艾姆帕格利夫洛辛 (Empagliflozin) 是一种血液动力学 血液动力学微神经扫描 (microneurography) 是一种微神经扫描.同情活动是同情活动.更多相关视频
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
209
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
209
Oral Hypoglycemic Agents: Sulfonylureas
212
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
212
Antihypertensive Drugs: Thiazide-Class Diuretics
680
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
680
Oral Hypoglycemic Agents: Glinides
157
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
157
Glucose Transporters
22.8K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.8K
Dipeptidyl Peptidase 4 Inhibitors
190
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190


